Tag: acute respiratory distress syndrome
Foresee Pharmaceuticals begins FP-025 phase 2/3 trial in Covid-19 associated ARDS
Foresee Pharmaceuticals has started patient dosing in a phase 2/3 trial of FP-025 in adults having severe to critical Covid-19 with associated acute respiratory distress ... Read More
Citius seeks FDA nod for evaluating stem cell therapy for ARDS in COVID-19
Citius Pharmaceuticals has made a Pre-IND submission to the US Food and Drug Administration for a novel stem cell therapy for acute respiratory distress syndrome ... Read More